135 related articles for article (PubMed ID: 14675312)
81. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
82. [Urinary tract surgery in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy].
Cascales PA; Gil J; Alarcón CM; Galindo P; Gómez G; Parrilla P
Cir Esp; 2012 Mar; 90(3):162-8. PubMed ID: 22341613
[TBL] [Abstract][Full Text] [Related]
83. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Hofstetter G; Concin N; Braicu I; Chekerov R; Sehouli J; Cadron I; Van Gorp T; Trillsch F; Mahner S; Ulmer H; Grimm C; Castillo-Tong DC; Zeillinger R; Zeimet AG; Vergote I
Gynecol Oncol; 2013 Oct; 131(1):15-20. PubMed ID: 23877013
[TBL] [Abstract][Full Text] [Related]
84. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
[TBL] [Abstract][Full Text] [Related]
85. The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.
Fagan PJ; Gomes N; Heath OM; Chandrasekaran D; Yao SE; Satchwell L; George A; Banerjee S; Sohaib A; Barton DP; Nobbenhuis M; Ind T; Butler J
Int J Gynecol Cancer; 2023 Nov; 33(11):1757-1763. PubMed ID: 37890875
[TBL] [Abstract][Full Text] [Related]
86. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.
Bijelic L; Jonson A; Sugarbaker PH
Ann Oncol; 2007 Dec; 18(12):1943-50. PubMed ID: 17496308
[TBL] [Abstract][Full Text] [Related]
87. Cytoreductive surgery for advanced epithelial tumors of the ovary: technical considerations and outcome.
Khalil el-SA; Fakhr I; Younis A; El-Shahawy M; Adel I
J Egypt Natl Canc Inst; 2005 Sep; 17(3):158-64. PubMed ID: 16799653
[TBL] [Abstract][Full Text] [Related]
88. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
89. Functional tumour volume and peritoneal carcinomatosis to identify suitable candidates for cytoreductive surgery in ovarian carcinoma: abridged secondary publication.
Lee EYP; Hui ESK; Ngan HYS
Hong Kong Med J; 2022 Feb; 28 Suppl 1(1):14-16. PubMed ID: 35260509
[No Abstract] [Full Text] [Related]
90. The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis.
Chuang CM; Chou YJ; Yen MS; Chao KC; Twu NF; Wu HH; Wen KC; Chen YJ; Wang PH; Lai CR; Chou P
Oncologist; 2012; 17(6):847-55. PubMed ID: 22591974
[TBL] [Abstract][Full Text] [Related]
91. Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.
Bhat RA; Chia YN; Lim YK; Yam KL; Lim C; Teo M
Oman Med J; 2015 Sep; 30(5):344-52. PubMed ID: 26421115
[TBL] [Abstract][Full Text] [Related]
92. Controversial aspects of cytoreductive surgery in epithelial ovarian cancer.
Hacker NF
Baillieres Clin Obstet Gynaecol; 1989 Mar; 3(1):49-57. PubMed ID: 2472243
[TBL] [Abstract][Full Text] [Related]
93. Papillary serous carcinoma of the peritoneum.
Chew S; Tham KF; Lim FK; Ratnam SS
J Obstet Gynaecol (Tokyo 1995); 1995 Aug; 21(4):341-7. PubMed ID: 8775903
[TBL] [Abstract][Full Text] [Related]
94. Safety and efficacy of a splenectomy during debulking surgery for Müllerian carcinoma.
Uehara T; Onda T; Togami S; Amano T; Tanikawa M; Sawada M; Ikeda S; Kato T; Kasamatsu T
Eur J Gynaecol Oncol; 2011; 32(3):269-73. PubMed ID: 21797114
[TBL] [Abstract][Full Text] [Related]
95. Primary serous papillary carcinoma of the peritoneum: a report of 18 patients.
Taus P; Petru E; Gücer F; Pickel H; Lahousen M
Eur J Gynaecol Oncol; 1997; 18(3):171-2. PubMed ID: 9174828
[TBL] [Abstract][Full Text] [Related]
96. Primary papillary serous carcinoma of the peritoneum in a man.
Shmueli E; Leider-Trejo L; Schwartz I; Aderka D; Inbar M
Ann Oncol; 2001 Apr; 12(4):563-7. PubMed ID: 11398893
[TBL] [Abstract][Full Text] [Related]
97. Primary peritoneal serous papillary carcinoma: a case series.
Blontzos N; Vafias E; Vorgias G; Kalinoglou N; Iavazzo C
Arch Gynecol Obstet; 2019 Oct; 300(4):1023-1028. PubMed ID: 31486887
[TBL] [Abstract][Full Text] [Related]
98. Recurrent ovarian carcinoma: is there a place for surgery?
Chen LM; Karlan BY
Semin Surg Oncol; 2000; 19(1):62-8. PubMed ID: 10883026
[TBL] [Abstract][Full Text] [Related]
99. Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy.
Pariury H; Golden C; Huh WW; Cham E; Chung T; Hayes-Jordan A
Pediatr Blood Cancer; 2019 Jul; 66(7):e27753. PubMed ID: 30977252
[TBL] [Abstract][Full Text] [Related]
100. Regional surgery in advanced ovarian carcinoma.
Magli G; De Marco I; Biello A; Turtoro L; Esposito A
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):97-8. PubMed ID: 1511723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
